Palisade Bio (NASDAQ:PALI) Issues Earnings Results, Beats Estimates By $1.70 EPS

Palisade Bio (NASDAQ:PALI) issued its quarterly earnings data on Monday. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($2.39) by $1.70, Zacks reports.

Palisade Bio Trading Down 1.4 %

Palisade Bio stock opened at $0.70 on Tuesday. Palisade Bio has a 1-year low of $0.66 and a 1-year high of $9.65. The firm’s fifty day simple moving average is $1.12 and its 200-day simple moving average is $2.17. The company has a market capitalization of $1.94 million, a P/E ratio of -0.05 and a beta of 1.49.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.